FISCAL NOTE
Date Requested: January 19, 2015 Time Requested: 02:11 PM |
Agency: |
Health and Human Resources, Department of |
CBD Number: |
Version: |
Bill Number: |
Resolution Number: |
2058 |
Introduced |
HB2046 |
|
CBD Subject: |
Health |
---|
|
FUND(S):
0407 - Division of Health Central Office General Administrative Fund 0407 - Division of Health Central Office General Administrative Fund 0407 - Division of Health Central Office General Administrative Fund
Sources of Revenue:
General Fund
Legislation creates:
Neither Program nor Fund
Fiscal Note Summary
Effect this measure will have on costs and revenues of state government.
The purpose of this bill is to allow for expedited partner therapy. It would permit prescribing antibiotics for the partner of a patient without first examining the partner. It requires counseling by the physician. The bill also requires the Department of Health and Human Resources to develop outreach materials. The bill has limited liability for physician, physician assistants and advance nurse practitioners who prescribe in an expedited partner therapy setting. The bill makes changes to the licensing portions of the code to make it permissible for the various disciplines to prescribe without disciplinary actions from their respective licensing boards.
The Department estimates that Expedited Partner Therapy (EPT) will double expenditures for the purchase of Sexually Transmitted Disease (STD) medications. When a newly diagnosed case of a bacterial STD is identified, the patient will further identify their sexual partner(s). To prevent reinfections of the patient and further transmission of the STD, the distributed treatment medication will be made available for the sexual partner(s). Therefore, the cost of providing such medications will be approximately double what the current estimated annual cost is ($46,495 for SFY2014).
By early detection and the increased access to early treatment, we anticipate a reduction in transmission and long term health care costs in the state
Fiscal Note Detail
Effect of Proposal |
Fiscal Year |
2015 Increase/Decrease (use"-") |
2016 Increase/Decrease (use"-") |
Fiscal Year (Upon Full Implementation) |
1. Estmated Total Cost |
0 |
46,495 |
55,794 |
Personal Services |
0 |
0 |
0 |
Current Expenses |
0 |
46,495 |
55,794 |
Repairs and Alterations |
0 |
0 |
0 |
Assets |
0 |
0 |
0 |
Other |
0 |
0 |
0 |
2. Estimated Total Revenues |
0 |
0 |
0 |
Explanation of above estimates (including long-range effect):
For fiscal year 2014, the following STDs were diagnosed and treated: Chlamydia - 5,023 and Gonorrhea - 990. Costs for medications to treat those diagnosed STD's in FY 2014 totaled $46,495 and consisted of the following medications used to treat those diagnosed STDs: Azithromycin - $ 16,763; Ceftriaxone - $ 1,470; Doxycycline - $ 23,565; Clindamycin - $ 1,310; Metronidazole - $ 1,622; and Podocon - $1,765. The increase in future years includes an estimated 20% increase in medication prices.
Memorandum
It is anticipated that through this legislation there will be more persons in the State that will be treated for sexually transmitted diseases, which will incur an associated cost for that treatment. However, there is not data available on how many of those persons would potentially be Medicaid members, or what specific treatments would be utilized in these situations. Therefore, it is not known how much of these increased costs for such treatment would be borne by the Medicaid program.
Person submitting Fiscal Note: Karen L. Bowling
Email Address: dhhrbudgetoffice@wv.gov